Syneos Health Releases Report Identifying Barriers to Payer Use of RWE in Rare Disease and Recommendations for Advancing Payer Engagement
Company Launches Syneos Health Insights Hub to Provide Biopharma Leaders with Actionable Insights Informed by Dynamic Research
MORRISVILLE, N.C. and NEW YORK , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released “,” a report identifying payer barriers to use of Real World Evidence (RWE) and opportunities to advance understanding and engagement. The report includes firsthand feedback – generated from the Syneos Health Payer Panel comprised of more than 300 payers in the U.S. and Europe – exploring the acceptability of RWE on payer decisions for rare therapies and perspectives on how their stance is likely to evolve over time.
Drug developers and global regulators are rapidly expanding RWE use to design, test and review rare disease treatments, unlocking the potential to speed innovative treatments to market. When used in tandem with other pricing and reimbursement innovations, RWE can contribute to a multi-dimensional value picture. However, payer perception surrounding RWE benefits for rare disease therapies lags behind the industry and regulators as payers may not be as receptive to or as familiar with RWE-based presentations.
“Our research reveals that payers are positively disposed to use RWE, but knowledge gaps around the validity and value of RWE must be closed to improve access for rare disease patients,” said Alistair Macdonald, Chief Executive Officer, Syneos Health. “Multi-stakeholder feedback points to the need for collaborative, well-structured exercises and standard-setting for payers to advance at the same velocity as other industry stakeholders. Dialogue is key, and the time to facilitate these conversations is now.”
Key Syneos Health Payer Panel survey findings include:
Language Barrier Indicates Need for Standard RWE Lexicon:
- European payers have greater familiarity with RWE and Real World Data (RWD) terminology that is routinely used by regulators in the U.S. and Europe.
- 55% of U.S. payers and 37% of European payers said RWD and RWE terminology is not used widely at their institutions.
Perception of RWE Benefits Varies Among Payers Worldwide:
- 60% of U.S. payers said RWE can provide robust data on how an agent has behaved in real-world conditions where population, diversity, comorbidities and adherence variability come into play, while only 42% of European payers say that RWE mirrored real-world conditions and would eventually inform clinical practices.
- Variations of RWE acceptance and influence exist across Europe. For example, RWE can influence payer decisions in Italy and Spain on national and regional levels, but in Germany, payers question the validity of RWE submitted by manufacturers.
RWE Data Submission Limitations:
- 100% of payers in the U.S. and Europe expressed a version of the view that all data are not equal in clinical decision making. Furthermore, there is no single accepted hierarchy of persuasive data on either side of the Atlantic.
- In the U.S., 100% voiced concern surrounding the lack of standardized – or even interoperable – electronic health records (EHRs), with more than half describing this barrier as the biggest limitation compared to European countries that have national health systems.
- 34% of European payers identified lack of standardization as the biggest limitation creating uncertainty around RWE utility.
Reputable Sources for Decision Making Point to Need to Leverage KOLs Whom Payers Trust:
- 77% of U.S. payers said primary peer-reviewed literature is “always meaningful” in their coverage decision making vs.48% in Europe.
- Subsequently, European payers put more trust in internal data, such as internal claims, health economics and outcomes research (HEOR) analysis from trusted academic or institutional partners (87%) than their U.S. counterparts (66%). European payers are also more likely to trust sponsor dossiers (42%) than U.S. payers (only 16%) seeing them as “always meaningful.”
“While payer engagement surrounding RWE in the rare disease space differs from industry and regulators, our research uncovers no trend or obstacles to advancing their understanding as long as regulatory bodies and industry groups are attentive to their concerns,” said Macdonald. “Our Insights Hub allows us to share these insights broadly across industry stakeholders to accelerate innovation and speed market access to change patients’ lives.”
, including qualitative feedback and recommendations for accelerating payer understanding. our cross-functional team who can help biopharmaceutical companies close evidentiary gaps across all therapeutic areas, including tapping into our robust Payer Panel.
Syneos Health Insights Hub – New Destination Provides Real Answers to Guide Biopharma Decision Making and Investment
The Syneos Health Insights Hub generates future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment. Driven by dynamic research, our perspectives are informed by our insights-driven product development model, curated by our subject matter experts and focused on real answers to customer challenges to help guide decision making and investment. Visit the .
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry-leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit .
About the “Real World Value: Advancing Payer Understanding of RWE in Rare Disease” Survey
The survey included 64 respondents, evenly divided between the U.S. and Europe (France, Germany, Italy, Spain, Sweden and the UK). All participants are on Pharmacy and Therapeutic (P&T) committees, have experience in rare disease, are involved in decision making for this category and also formulate medical policies.
Syneos Health Investor Relations Contact:
Ronnie Speight
Senior Vice President, Investor Relations
Syneos Health Press/Media Contact:
Danielle DeForge
Executive Director, External Communications
